Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as ...

Glaukos' fourth-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx ...

Truist Financial analyst Richard Newitter maintained a Buy rating on Glaukos (GKOS – Research Report) today. The company’s shares closed ...

Needham raised the firm’s price target on Glaukos (GKOS) to $176 from $149 and keeps a Buy rating on the shares after its Q4 results. The ...

Fintel reports that on February 19, 2025, Mizuho upgraded their outlook for Glaukos (NYSE:GKOS) from Neutral to Outperform.

Glaukos Corp (NYSE:GKOS) is set to release its Q4 2024 earnings on Feb 20, 2025. The consensus estimate for Q4 2024 revenue ...

Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ETCompany ParticipantsChris Lewis - Vice President, ...

The results surpassed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 43 cents per share. The glaucoma treatments developer ...

Rhumbline Advisers lifted its holdings in Glaukos Co. (NYSE:GKOS – Free Report) by 0.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The ...

State of New Jersey Common Pension Fund D grew its position in Glaukos Co. (NYSE:GKOS – Free Report) by 2.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 19,883 shares of the ...